Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1653 1657 1699
This examiner grants 54% of resolved cases
Nghi V Nguyen operates in Art Unit 1641 of Tech Center 1600, where 494 cases have reached a resolution. The allowance rate for these matters is 53.6%, providing a clear picture of the probability of a grant. This 53.6% rate is a central feature of the examiner's historical data across his 494 resolved cases.
The median days to allowance is 1318, which serves as a benchmark for the time required to complete the prosecution process. Applicants should prepare for a timeline of 1318 days when their cases are allowed. This duration is a consistent metric that practitioners can use for planning and client communication.
A notable interview lift of 50.8% is recorded for this examiner. This lift indicates that the chance of allowance increases significantly when an interview is held compared to the 53.6% baseline. Given the 1318-day median, an interview appears to be a highly effective strategy for reaching a positive outcome. These figures together characterize the examination style in Art Unit 1641.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17479037 | CELL CULTURE CARRIER, AND METHOD AND DEVICE FOR PRODUCING SAME | Non-Final OA | RICOH COMPANY, LTD. |
| 17609064 | WASHED PLATELET EXTRACT | Final Rejection | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 19395349 | USE OF PASTEURIZED AKKERMANSIA FOR TREATING METABOLIC DISORDERS | Final Rejection | COMPAGNIE GERVAIS DANONE |
| 17434912 | A NUTRITIONAL COMPOSITION FOR USE TO ENHANCE EXECUTIVE FUNCTION | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 17908810 | METHODS AND SYSTEMS TO PRINT AND MATURE TISSUES OVER TIME IN A THREE-DIMENSIONAL SUPPORT MATRIX | Non-Final OA | The General Hospital Corporation |
| 17915086 | METHODS, COMPOSITIONS, AND SYSTEMS FOR ENHANCING EX-VIVO ORGAN PERFUSION | Final Rejection | University Health Network |
| 18553997 | IMPROVED ADDITIVE SOLUTION FOR WHOLE BLOOD PRESERVATION AND STORAGE | Non-Final OA | University Of Cincinnati |
| 18264396 | MESENCHYMAL STEM CELLS AND ADIPOCYTES FOR PREPARING MITOKINE MIXTURE, AND THERAPEUTIC OR PROPHYLACTIC DRUG | Final Rejection | TOKYO UNIVERSITY OF SCIENCE FOUNDATION |
| 18554103 | DOPAMINERGIC PRECURSOR CELLS AND METHODS OF USE | Non-Final OA | FUJIFILM Cellular Dynamics, Inc. |
| 18363642 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18342676 | METHODS OF GENERATING MYCELIAL SCAFFOLDS AND APPLICATIONS THEREOF | Non-Final OA | Ecovative LLC |
| 15107152 | CONVERGENCE OF AGGREGATION RATE WITH VALIDATED PERIPHERAL DIAGNOSTIC FOR ALZHEIMER'S DISEASE | Final Rejection | West Virginia University |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy